doi:10.19982/j.issn.1000-6621.20220249

Abstract

CLC Number:

R593
R52

References 22

[1]	邓国防, 付亮. 浅谈风湿免疫性疾病并发结核感染的诊治现状. 结核病与肺部健康杂志, 2018, 7(2):88-90. doi: 10.3969/j.issn.2095-3755.2018.02.002. doi: 10.3969/j.issn.2095-3755.2018.02.002
[2]	Anton C, Machado FD, Ramirez JMA, et al. Latent tuberculosis infection in patients with rheumatic diseases. J Bras Pneumol, 2019, 45(2): e20190023. doi: 10.1590/1806-3713/e201 90023. doi: 10.1590/1806-3713/e201 90023 URL
[3]	Garziera G, Morsch ALB, Otesbelgue F, et al. Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents. Clin Rheumatol, 2017, 36(8):1891-1896. doi: 10.1007/s10067-017-3714-6. doi: 10.1007/s10067-017-3714-6 pmid: 28589321
[4]	Long W, Cai F, Wang X, et al. High risk of activation of latent tuberculosis infection in rheumatic disease patients. Infect Dis (Lond), 2020, 52(2):80-86. doi: 10.1080/23744235.2019.1682187. doi: 10.1080/23744235.2019.1682187
[5]	Pettipher C, Benitha R. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO). Ann Rheum Dis, 2020, 79(2):292-299. doi: 10.1136/annrheumdis-2019-216128. doi: 10.1136/annrheumdis-2019-216128 pmid: 31791950
[6]	王子浔, 荣兰香, 马淑红, 等. 风湿免疫性疾病患者行T-SPOT.TB检测筛查潜伏性结核感染的价值. 中国实验诊断学, 2017, 21(3):512-514. doi: 10.3969/j.issn.1007-4287.2017.03.047. doi: 10.3969/j.issn.1007-4287.2017.03.047
[7]	黄安芳, 罗妍, 赵毅, 等. 风湿病患者合并潜伏性结核感染的分析. 中华内科杂志, 2016, 55(4): 307-310. doi: 10.3760/cma.j.issn.0578-1426.2016.04.012. doi: 10.3760/cma.j.issn.0578-1426.2016.04.012
[8]	邓国防, 王玉香, 陈涛, 等. 风湿免疫性疾病并发结核感染的临床特征分析. 中国防痨杂志, 2018, 40(4):392-396. doi: 10.3969/j.issn.1000-6621.2018.04.009. doi: 10.3969/j.issn.1000-6621.2018.04.009
[9]	刘羽佳, 徐婧, 郭倩, 等. 慢性炎症性关节炎患者潜伏性结核感染的发生率及不同筛查方法的诊断价值. 中华医学杂志, 2019, 99(1):20-24. doi: 10.3760/cma.j.issn.0376-2491.2019.01.005. doi: 10.3760/cma.j.issn.0376-2491.2019.01.005
[10]	中华医学会结核病学分会. 结核分枝杆菌γ-干扰素释放试验及临床应用专家意见(2021年版). 中华结核和呼吸杂志, 2022, 45(2):143-150. doi: 10.3760/cma.j.cn112147-20211110-00794. doi: 10.3760/cma.j.cn112147-20211110-00794
[11]	Ruan Q, Zhang S, Ai J, et al. Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysis. Clin Rheumatol, 2016, 35(2): 417-425. doi: 10.1007/s10067-014-2817-6. doi: 10.1007/s10067-014-2817-6 URL
[12]	Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 2016, 13(10):e1002152. doi: 10.1371/journal.pmed.1002152. doi: 10.1371/journal.pmed.1002152 URL
[13]	Liu X, Zhang L, Zhang F, et al. Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China. Emerg Microbes Infect, 2021, 10(1):2303-2312. doi: 10.1080/22221751.2021.2004864. doi: 10.1080/22221751.2021.2004864 URL
[14]	World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization, 2021.
[15]	Lao M, Chen D, Wu X, et al. Active tuberculosis in patients with systemic lupus erythematosus from Southern China: a retrospective study. Clin Rheumatol, 2019, 38(2):535-543. doi: 10.1007/s10067-018-4303-z. doi: 10.1007/s10067-018-4303-z URL
[16]	唐果, 龙丽, 韩雅欣, 等. 类风湿关节炎合并结核感染的临床特点及相关因素. 北京大学学报(医学版), 2020, 52(6):1029-1033. doi: 10.19723/j.issn.1671-167X.2020.06.007. doi: 10.19723/j.issn.1671-167X.2020.06.007
[17]	左晓霞. 结缔组织疾病患者结核感染的研究现状与思考. 中华风湿病学杂志, 2009, 13(10): 657-659. doi: 10.3760/cma.j.issn.1007-7480.2009.10.001. doi: 10.3760/cma.j.issn.1007-7480.2009.10.001
[18]	李良豪, 董志豪, 杨毅, 等. 三例高原地区使用糖皮质激素诱发肺结核并恶化临床思考. 中国保健营养, 2020, 30(5):160.
[19]	卫菁, 蔡俊, 张忠华. 肿瘤坏死因子-α拮抗剂致结核文献分析. 中国医院药学杂志, 2019, 39(11): 1171-1174,1178. doi: 10.13286/j.cnki.chinhosppharmacyj.2019.11.13. doi: 10.13286/j.cnki.chinhosppharmacyj.2019.11.13
[20]	陈涛, 张培泽, 付亮, 等. 不同类型风湿性疾病合并结核病临床特点分析. 新发传染病电子杂志, 2021, 6(2):101-104. doi: 10.19871/j.cnki.xfcrbzz.2021.02.006. doi: 10.19871/j.cnki.xfcrbzz.2021.02.006
[21]	中华人民共和国国家卫生和计划生育委员会. WS 288-2017肺结核诊断.2017-11-09.
[22]	依那西普治疗类风湿关节炎和强直性脊柱炎专家组. 依那西普治疗类风湿关节炎和强直性脊柱炎的专家建议. 中华内科杂志, 2010, 49(6):546-549. doi: 10.3760/cma.j.issn.0578-1426.2010.06.030. doi: 10.3760/cma.j.issn.0578-1426.2010.06.030

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 22

Related Articles 9

Recommended Articles

Metrics

Comments

[1]	Zhang Lifan, Chen Yan, Zhang Yueqiu, Zhang Fengchun, Zeng Xiaofeng, Zhao Yan, Liu Shengyun, Zuo Xiaoxia, Zhang Zhiyi, Wu Huaxiang, Chen Sheng, Li Hongbin, Zhu Ping, Wu Lijun, Qi Wencheng, Liu Yi, Zhang Miaojia, Liu Huaxiang, Zhou Baotong, Shi Xiaochun, Ruan Guiren, Liu Xiaoqing, The Epidemiological Study and Therapeutic Evaluation of Rheumatic Patients with Tuberculosis Study Team. Prevalence of active tuberculosis in Chinese patients with rheumatic diseases: A multicenter cross-sectional subgroup analysis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 22-28.
[2]	Zhang Lifan, Ma Yanan, Zou Xiaoqing, Zhang Yueqiu, Zhang Fengchun, Zeng Xiaofeng, Zhao Yan, Liu Shengyun, Zuo Xiaoxia, Wu Huaxiang, Wu Lijun, Li Hongbin, Zhang Zhiyi, Chen Sheng, Zhu Ping, Zhang Miaojia, Qi Wencheng, Liu Yi, Liu Huaxiang, Shi Xiaochun, Liu Xiaoqing, the Epidemiological Study and Therapeutic Evaluation of Rheumatic Patients with Tuberculosis Study Team. Latent tuberculosis infection rate and risk factors in patients with rheumatic diseases: a multi-center, cross-sectional study [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 29-39.
[3]	Zhou Qian, Deng Guofang, Wang Qingwen. Retrospective analysis of clinical intervention and follow-up of patients with systemic lupus erythematosus complicated with tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1294-1302.
[4]	Xie Jingyi, Zou Ruifeng, Chen Yulan, Chen Yong, Liu Dongzhou, Hong Xiaoping. Analysis of clinical features and peripheral lymphocyte subsets of systemic lupus erythematosus patients complicated with tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 911-916.
[5]	Wu Wenqi, Zhong Jianqiu, He Juan, Deng Guofang, Wang Qingwen. The research progress of the reactivation of latent tuberculosis infection in patients with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 954-959.
[6]	Han Xu, Guan Shangqi, Shi Yinpeng, Mei Yifang. The risk of tuberculosis infection with non-tumor necrosis factor-targeted drugs in the treatment of rheumatoid arthritis [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 966-972.
[7]	Chen Qiuqi, Han Tingting, Wang Qingwen, Deng Guofang. Recent advances in treatment of latent tuberculosis infection complicated with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 960-965.
[8]	National Clinical Research Centre for Infectious Disease/The Third People’s Hospital of Shenzhen, Peking University Shenzhen Hospital, Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Shenzhen Key Laboratory of Inflammatory and Immune Diseases. Expert consensus on diagnosis and treatment of latent tuberculosis infection in patients with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 869-879.
[9]	Zhang Tongmei,Qin Na,Lu Baohua,Wang Jingping,Li Baolan. Clinical analysis on diagnosis of sarcoidosis in 45 patients [J]. Chinese Journal of Antituberculosis, 2011, 33(5): 285-289.